Scholarlink

Background <p>This study evaluates the long-term efficacy and safety of intravitreal 0.19&#xa0;mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone implant (DEXAi).</p> Methods <p>A retrospective review of patients with chronic non-infectious UME who received intravitreal FAi after STTA and/or DEXAi.</p> Results <p>Thirteen eyes from 7 patients (69.2% female) were included, with a mean age of 65 ± 11 years. The median follow-up was 54 months before FAi (IQR: 43–65) and 47 months after FAi (IQR: 23–60). All eyes received at least one STTA, and 11 eyes received at least one DEXAi before FAi. The median number of injections before FAi was 4 (range: 2–8). A significant reduction in recurrences per year was observed after FAi (4.62 ± 1.9 before vs. 0.31 ± 0.5 after, Wilcoxon test, <i>p</i> = 0.001). Macular edema relapsed in 4 eyes (30.8%) between months 28 and 36. Central retinal thickness significantly decreased after FAi (474 ± 96&#xa0;μm before vs. 305 ± 58&#xa0;μm after, Wilcoxon test, <i>p</i> = 0.002). Ten eyes (76.9%) showed BCVA improvement (1–4 lines), and none lost visual acuity. All eyes were pseudophakic prior to FAi. At FAi, four of seven patients were on systemic anti-inflammatory therapy; 3 discontinued it, and none started new treatment after FAi. Five eyes were on topical IOP-lowering medication at the time of FAi; 2 required and increase in treatment, and 2 later underwent trabeculectomy. After FAi, only two eyes started IOP-lowering medication.</p> Conclusions <p>In this case series with long-term follow-up, FAi for non-infectious UME was effective, safe, and reduced recurrences compared to other local corticosteroids.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月8日

查看全文
  • Ana Margarida Ferreira,
  • Marta Inês Silva,
  • Sónia Torres-Costa,
  • Cláudia Oliveira-Ferreira,
  • Ana Catarina Pedrosa,
  • Luís Figueira,
  • Joana Rodrigues Araújo

摘要

Background

This study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone implant (DEXAi).

Methods

A retrospective review of patients with chronic non-infectious UME who received intravitreal FAi after STTA and/or DEXAi.

Results

Thirteen eyes from 7 patients (69.2% female) were included, with a mean age of 65 ± 11 years. The median follow-up was 54 months before FAi (IQR: 43–65) and 47 months after FAi (IQR: 23–60). All eyes received at least one STTA, and 11 eyes received at least one DEXAi before FAi. The median number of injections before FAi was 4 (range: 2–8). A significant reduction in recurrences per year was observed after FAi (4.62 ± 1.9 before vs. 0.31 ± 0.5 after, Wilcoxon test, p = 0.001). Macular edema relapsed in 4 eyes (30.8%) between months 28 and 36. Central retinal thickness significantly decreased after FAi (474 ± 96 μm before vs. 305 ± 58 μm after, Wilcoxon test, p = 0.002). Ten eyes (76.9%) showed BCVA improvement (1–4 lines), and none lost visual acuity. All eyes were pseudophakic prior to FAi. At FAi, four of seven patients were on systemic anti-inflammatory therapy; 3 discontinued it, and none started new treatment after FAi. Five eyes were on topical IOP-lowering medication at the time of FAi; 2 required and increase in treatment, and 2 later underwent trabeculectomy. After FAi, only two eyes started IOP-lowering medication.

Conclusions

In this case series with long-term follow-up, FAi for non-infectious UME was effective, safe, and reduced recurrences compared to other local corticosteroids.